Abstract:Background: Oxaliplatin is used in adjuvant treatment of colorectal cancer and is associated with sinusoidal obstruction syndrome. Few data are available on its effects in patients in whom portal hypertension was diagnosed before cancer treatment. Objective: Our aim was to investigate short- and long-term outcomes of surgery for colorectal cancer in patients with portal hypertension with or without cirrhosis, particularly regarding effects of adjuvant chemotherapy with oxaliplatin. Design and setting: This was a prospective cohort study performed at an academic medical center. Patients: Patients with stage II or III colorectal cancer and portal hypertension who underwent curative resection were included. Intervention: All patients received adjuvant chemotherapy with oxaliplatin (FOLFOX 4) or 5-fluorouracil and leucovorin. Main outcome measures: Potential predictive laboratory and clinical variables and postoperative (30-day) and long-term morbidity and mortality were recorded. Results: Of 63 patients enrolled, 23 (37%) had a total of 82 postoperative complications; 5 patients (8%) died within 30 days postoperatively. Univariate analysis showed that severe portal hypertension, preoperative Child class B, low albumin, the presence of ascites, preoperative upper GI tract bleeding, and high intraoperative blood loss were linked to postoperative morbidity. Presence of postoperative infection (p = 0.004), presence of preoperative ascites (p = 0.01), high intraoperative blood loss (p = 0.02), and preoperative upper GI tract bleeding (p = 0.03) were significantly related to mortality. Of 58 patients receiving adjuvant chemotherapy, 20 received the oxaliplatin regimen and 38 received 5-fluorouracil/leucovorin without oxaliplatin. The median length of follow-up was 26 (range, 6-36) months. Kaplan-Meier analyses showed that patients who received oxaliplatin had higher cumulative incidences of newly developed esophageal varices (p = 0.002), GI tract bleeding (p = 0.02), and newly formed ascites (p = 0.03). Death occurred in 8 of 20 patients (40%) in the oxaliplatin group and in 5 of 38 patients (13%) in the 5-fluorouracil group. Kaplan-Meier estimates of mean survival time were 34.4 months (95% CI, 32.4-36.5) in the 5-fluorouracil/leucovorin group vs 29.9 months (95% CI, 26-33.7) in the oxaliplatin group, and patients receiving oxaliplatin had a significantly higher relative risk of death (HR = 2.98; 95% CI, 1.03-8.65). Cancer-specific mortality was not related to treatment type. Limitations: The study was limited by the relatively small sample size and lack of randomization, which may have led to selection bias in treatment regimens. Conclusions: Colorectal cancer surgery can be done safely in portal hypertensive patients with good hepatic function; however, higher mortality is expected in patients with compromised hepatic function reserve. Compared with adjuvant chemotherapy without oxaliplatin, oxaliplatin-based chemotherapy does not significantly reduce cancer-specific mortality and may increase overall morbidity and mortality. Therefore, oxaliplatin-based chemotherapy should be used with caution in patients who have portal hypertension, even in those with good liver function.

Liver cirrhosis following oxaliplatin-based adjuvant chemotherapy for rectal cancer

The "appearing" and "disappearing" ascites in the treatment of colorectal cancer: a case report

Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?

Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer

Case Report: Oxaliplatin-induced Idiopathic Non-Cirrhotic Portal Hypertension: a Case Report and Literature Review

Oxaliplatin-related Portal Hypertension Complicated with Esophageal Varices and Refractory Massive Ascites

Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer

Oxaliplatin-based Adjuvant Chemotherapy Without Radiotherapy Can Improve the Survival of Locally-Advanced Rectal Cancer.

Clinical Features of Hypersensitivity Reactions to Oxaliplatin among Chinese Colorectal Cancer Patients

Clinical features of hypersensitivity reactions to oxaliplatin among Chinese patients with colorectal cancer

Successful Treatment of Colorectal Liver Metastasis Harboring Intrahepatic Cholangiocarcinoma

Clinical research on oxaliplatin or irinotecan plus capecitabine for colorectal liver metastasis treatment

Adjuvant Chemotherapy Containing Oxaliplatin Without Radiotherapy to Improve Survival of Local Advanced Low and Middle Rectal Cancer

S4296 Oxaliplatin-Induced Non-Cirrhotic Portal Hypertension

Misdiagnosis of severe and atypical oxaliplatin‑related hypersensitivity reaction following chemotherapy combined with PD‑1 inhibitor: A case report and literature review

Focal nodular hyperplasia after oxaliplatin-based chemotherapy: A diagnostic challenge

Arterial infusion of Oxaliplatin for treatment of liver metastases from colorectal cancer after surgery

Short-term efficacy of oxaliplatin as interventional therapy for liver cancer, and its effect on serum CD163 and AFU

Addition of Oxaliplatin to Capecitabine-Based Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Long-term Outcome of a Phase II Study.